SLC6A11 and Rett syndrome: This is evidenced either via elevating GAT3/4 activity, in a Rett syndrome rodent model, leading to a lowered tonic inhibition (Dong et al., 2020), or reducing the transporter expression, in a Parkinsonian rodent model, leading to an increase in tonic inhibition (Chazalon et al., 2018).